HomeGroupsTalkZeitgeist
Big news! LibraryThing is now free to all! Read the blog post and discuss the change on Talk.
dismiss
This site uses cookies to deliver our services, improve performance, for analytics, and (if not signed in) for advertising. By using LibraryThing you acknowledge that you have read and understand our Terms of Service and Privacy Policy. Your use of the site and services is subject to these policies and terms.

Xiaogang Li

MembersReviewsRatingFavorited   Events   
0000
    No works currently cataloged.

Top members (works)

None

Recently added

None

Member favorites

Members: None

Add to favorites

No tags.

No events listed. (add an event)
You must log in to edit Common Knowledge data.
For more help see the Common Knowledge help page.
Canonical name
Legal name
Other names
Date of birth
Date of death
Burial location
Gender
Nationality
Country (for map)
Birthplace
Place of death
Places of residence
Education
Occupations
Relationships
Organizations
Awards and honors
Agents
Short biography
Xiaogang Li, PhD, is the Director of the Epigenetics Core at the Kansas Polycystic Kidney Disease (PKD) Research and Translational Core Center, supported by the National Institutes of Health of the United States of America (USA). He is Associate Professor of Internal Medicine at the University of Kansas Medical Center (KUMC), USA. He also holds academic appointments at the Departments of Biochemistry and Molecular Biology, Anatomy and Cell Biology, and Cancer Biology at KUMC. His research encompasses both basic science and translational aspects of PKD. In particular, he is widely regarded as one of the world’s foremost authorities on epigenetics and renal inflammation in PKD. Furthermore, he re-evaluates the roles of apoptosis in autosomal dominant PKD, contributing to a better understanding of the mechanisms of this disease. He has published extensively in the field including publications in Nature Cell Biology, Nature Medicine, and Journal of Clinical Investigation. His studies are leading to the use of promising new therapeutic drugs in PKD treatment.
Disambiguation notice

Is this you?

Become a LibraryThing Author.

Member ratings

Average: No ratings.

Improve this author

Combine/separate works

Author division

Xiaogang Li is currently considered a "single author." If one or more works are by a distinct, homonymous authors, go ahead and split the author.

Includes

Xiaogang Li is composed of 1 name.

Combine with…

 

About | Contact | Privacy/Terms | Help/FAQs | Blog | Store | APIs | TinyCat | Legacy Libraries | Early Reviewers | Common Knowledge | 144,153,474 books! | Top bar: Always visible